Up to 50% of patients with refl ux symptoms do not manifest a satisfactory symptom response to proton pump inhibitor (PPI) therapy. Our primary aim in this study was to identify factors associated with symptom perception among PPI non-responder phenotypes.
INTRODUCTION
Th e prevalence of gastroesophageal refl ux disease (GERD) in the United States is estimated to be >20% ( 1, 2 ) . Although acid suppression with proton pump inhibitor (PPI) therapy is extremely eff ective at healing erosive GERD, <50% of patients are satisfi ed with symptom control with PPI therapy ( 3, 4 ) . Given the high prevalence of GERD and rates of PPI non-response, the healthcare burden of PPI non-responders is substantial ( 5 ) .
Currently, a well-defi ned therapeutic algorithm for PPI nonresponders is lacking. Th is defi cit relates largely to heterogeneous physiological profi les and a poor understanding of the factors driving symptom perception in PPI non-responders ( 5 ) . Up to 50% of PPI non-responders have normal physiological and anatomical profi les (i.e., normal esophageal acid exposure, an intact antirefl ux barrier, and the absence of a major motility disorder) ( 6 ) . Despite a lack of objective evidence of refl ux, patients oft en Psychosocial Distress and Quality of Life Impairment Are Associated With Symptom Severity in PPI Non-Responders With Normal Impedance-pH Profi les perceive troublesome symptoms of refl ux. Understanding symptom genesis in PPI non-responders with normal refl ux testing is of great interest and has the potential to guide individualized and eff ective treatment strategies ( 7 ) .
In this study, our aim was to identify predictors of patient reported symptom severity among PPI non-responder phenotypes based on impedance-pH profi les. We hypothesized that psychosocial distress is associated with symptom severity among PPI non-responders with normal impedance-pH profi les.
METHODS

Study design and setting
We performed a prospective observational cohort study from September 2014 to January 2017 at a single academic medical center. Th e Northwestern University Institutional Review Board approved this study and participants provided written informed consent.
Participants
Eligible participants included adult patients (age ≥18 years) who underwent high-resolution esophageal manometry and 24-h combined multichannel intraluminal impedance and pH monitoring (MII-pH) while on or off PPI therapy for evaluation of troublesome esophageal symptoms despite at least 8 weeks of double dose PPI therapy. Patients undergoing evaluation prior to or following lung transplant, with a diagnosis of scleroderma, or with a major esophageal motility disorder of achalasia (types 1, 2, or 3), esophagogastric junction (EGJ) outfl ow obstruction, absent contractility, hypercontractile esophagus, or distal esophageal spasm were excluded.
Data source and measurement
Prior to MII-pH testing, participants completed a self-administered questionnaire set to obtain a baseline assessment of symptom burden, quality of life (QOL), and symptom-specifi c anxiety, discomfort, aff ect, and stress. Patient-reported symptom questionnaires included the GerdQ, a validated instrument for evaluating GERD symptoms ( 8 ) , the Refl ux Symptom Index, a validated laryngeal symptom questionnaire ( 9, 10 ) , and the Impaction-Dysphagia Questionnaire (IDQ) and Brief Esophageal Dysphagia Questionnaire (BEDQ), symptom questionnaires to evaluate dysphagia symptoms ( 11, 12 ) . QOL was measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Global 10 Survey ( 13 ). Symptom-specifi c psychosocial distress was measured using the Discomfort Intolerance Scale ( 14 ) , a measure of the ability to tolerate uncomfortable sensations, the Heartburn Vigilance Scale, adapted from the validated Pain Vigilance and Awareness Questionnaire ( 15, 16 ) , and the Brief Symptom Inventory, a validated psychosocial symptom scale ( 17 ) . For all questionnaires, a higher score indicated increased severity, impairment, and/or distress.
We additionally collected baseline clinical data for each participant including age, gender, symptoms, PPI dosage, size of hiatal hernia, and endoscopy results, as well as physiological data, including MII-pH results of the percentage of time esophageal acid exposure was below a pH of 4.0 (acid exposure time (AET)), number of refl ux episodes, symptom-refl ux association (SRA) using the symptom index and symptom association probability, and number of refl ux-associated symptoms (Sandhill Scientifi c, Highlands Ranch, CO), and high-resolution esophageal manometry results of motility diagnosis according to Chicago Classification version 3.0 ( 17 ), median integrated relaxation pressure, mean distal contractile integral, and the EGJ contractile integral (Manoscan 360; Medtronic, Minneapolis, MN).
AET>5.0% was considered abnormal. Positive SRA required a symptom index >50% in the setting of a symptom association probability >95%.
Outcomes
Th e primary outcome was patient-reported GERD symptom severity measured by the GerdQ score, a validated six-item patient-reported outcome tool for GERD that calculates symptom severity over the preceding week based on response to four positive predictors (heartburn, regurgitation, sleep disturbance, and antacid use) and two negative predictors (epigastric pain and nausea) of GERD. Scores range from 0 to 18; a higher GerdQ indicates greater symptom severity and a score of 8 is the proposed cutoff ( 8 ) . In this study, the primary outcome was dichotomized as abnormal GerdQ score (≥8) or normal GerdQ score (<8).
Data analysis
A complete case analysis was performed and missing data was not imputed. All eligible cases from 15 September 2014 to date of fi nal data collection, 23 January 2017, were included without a predetermined sample size. Baseline data, physiological data, and questionnaire scores were compared among the three profi les using analysis of variance for continuous variables and chi-square analysis for categorical variables.
Th e primary analysis included the cohort of participants who underwent MII-pH ON PPI. For the primary analysis, participants were categorized into three profi les based on their MII-pH on PPI profi le: −AET/−SRA, +AET, −AET/+SRA.
As data from MII-pH ON PPI can include GERD overlap, we performed a post hoc analysis of a cohort of participants who underwent MII-pH OFF PPI. For the secondary analysis participants were categorized into three profi les based on their MII-pH off PPI profi le: functional (−AET/−SRA), GERD (+AET), and refl ux hypersensitivity (RHS) (−AET/+SRA).
Both analyses aimed to identify predictors of abnormal GerdQ scores among the PPINR profi les. For each analysis, bivariate diff erences in baseline clinical variables, physiological data, and questionnaire scores between participants with an abnormal GerdQ (≥8) vs. normal GerdQ (<8) score were analyzed via two-tailed t -test or Mann-Whitney U -test for continuous variables as appropriate, and chi-square analysis for categorical variables. P -values <0.05 were considered signifi cant. All analyses were conducted using STATA 14.2 (StataCorp, College Station, TX).
RESULTS
Participants
Over the study period, 298 PPI non-responders underwent MIIpH and completed the questionnaire set (99 off PPI and 199 on PPI). One hundred and six met exclusion criteria (12 with a history of scleroderma, 34 for before/aft er lung transplant, 10 without complete GerdQ scores, and 50 with a major motility disorder). Th us this data analysis includes 192 participants (67 off PPI and 125 on PPI).
Primary analysis-MII-PH on PPI therapy
Baseline characteristics . Based on MII-pH on PPI results, the 125 participants were grouped as follows: 72 (58%) −AET/−SRA, 42 (34%) +AET, and 11 (9%) −AET/+SRA. Table 1 displays the baseline characteristics of these cohorts. Th e groups were balanced with regards to distribution of age and sex. Notably, the +AET cohort had a higher proportion of hiatal hernias >3 cm in size (33% vs. 8%, P <0.01) and symptoms of heartburn (69% vs. 42%, P =0.02) compared with the −AET/−SRA group. Compared with the −AET/−SRA group, both the +AET and −AET/+SRA groups had signifi cantly lower EGJ contractile integrals (71.4±49.7 vs. 49.7 47.4 and 43.6±24.9 mm Hg, P <0.05 for both comparisons). With regards to questionnaire data, the BEDQ score was significantly higher in the +AET group (8.2±7.8) compared with the − AET/−SRA group (4.5±6.7; P =0.02).
Predictors of abnormal GerdQ score by PPI non-responder profi le . Among the −AET/−SRA group, 63% had an abnormal GerdQ (≥8). Compared with those with a normal GerdQ, the −AET/−SRA group with an abnormal GerdQ was younger (53.3±15.1 vs. 46.6±12.3 years, P =0.05). Th ere were no significant diff erences between physiological data. With regards to questionnaire results, the −AET/−SRA group with an abnormal GerdQ compared with those with a normal GerdQ reported a signifi cantly higher mean Refl ux Symptom Index score (24.9±10.8 vs. 15.5±9.2, P <0.01), median IDQ score (8 (1-14) vs. 1 (0-4), P <0.01), mean BEDQ score (5.7±7.6 vs. 2.2±3.4, P =0.04), mean PROMIS QOL score (24.3±10.8 vs. 18.1±9.3, P =0.02), and median Brief Symptom Inventory score (10 (8.5-23.5) vs. 5 (1-11), P =0.02) ( Table 2 ) .
Among the +AET group, 64% had an abnormal GerdQ. Compared with those with a normal GerdQ, the +AET group with an abnormal GerdQ more oft en presented with heartburn (47% vs. 81%, P =0.02) and regurgitation (7% vs. 41%, P =0.02). Th ose with an abnormal GerdQ had a signifi cantly higher number of refl uxassociated symptoms (0.5±0.9 vs. 3.9±6.0, P =0.04) and greater proportion with a positive SRA (17 vs. 58%, P =0.02) on MII-pH testing, as well as a signifi cantly lower distal contractile integral (1,786±1,141 vs. 910±1,010 mm Hg-s-cm, P =0.05) on manometry. Th ere were no signifi cant diff erences between questionnaire scores ( Table 3 ) .
Among the 11 RHS participants, 8 (73%) had an abnormal GerdQ score. Descriptive data are available in Supplementary  Table S1 online. Given the small sample size, further analysis of this group was not conducted.
Post hoc analysis-MII-pH off PPI therapy
Based on MII-pH results off PPI therapy, the 67 participants were grouped as follows: 39 (58%) functional, 16 (24%) GERD, and 12 (18%) RHS. Compared with the GERD and RHS groups, the functional group had a higher proportion of females (44% and 58%, vs. 74%, respectively, P =0.07). Among the functional group, 29% had a normal GerdQ score, whereas among the GERD group only 1 patient had a normal GerdQ score and among the RHS group no participants had a normal GerdQ score. Th us predictors of abnormal GerdQ score were only examined among the functional group.
Predictors of abnormal GerdQ score among PPI non-responder functional profi les
Compared with those with a normal GerdQ, functional participants with an abnormal GerdQ less oft en presented with laryngeal complaints (47% vs. 6%, P <0.01). Th ere were no signifi cant diff erences between physiological testing. With regards to questionnaire scores, the functional participants reporting an abnormal GerdQ had higher IDQ scores and PROMIS Global QOL scores, though not statistically signifi cant ( Table 4 ) .
DISCUSSION
A primary treatment goal in the management of PPI nonresponse is the reduction of patient-reported symptom severity. However, PPI non-responders are not one in the same, and symptom genesis in functional heartburn undoubtedly diff ers from symptom genesis in PPI refractory GERD. As such, individualized treatment approaches for PPI non-responder phenotypes are essential to improving patient-reported outcomes. In this prospective observational study of 192 PPI non-responders, we examined factors associated with symptom perception within PPI non-responder phenotypes based on MII-pH monitoring results. Heightened symptom severity in the functional (−AET/− SRA off PPI) and functional±GERD overlap (−AET/−SRA on PPI) groups was associated with greater perceptions of dysphagia, psychosocial distress, and impaired quality of life, whereas physiological data did not diff er by symptom severity. Conversely, symptom severity in the PPI refractory GERD (+AET on PPI) or GERD (+AET off PPI) group was associated with physiological diff erences such as SRA and reduced esophageal contractility ( Figures 1 and 2 ). Th ese results suggest that mechanisms of symptom perception are heterogeneous across PPI non-responder phenotypes, and individualizing therapies for PPI non-responder phenotypes is of therapeutic value.
Keefer et al. ( 18 ) previously demonstrated that esophageal hypervigilance, the heightened awareness of esophageal discomfort coupled with behavior out of proportion to the symptom experience, is elevated among PPI non-responders, regardless of physiological profi le. Th is important work recognizes hypervigilance as a therapeutic target of PPI non-response across all levels of acid burden. In addition, prior studies report an association between symptom severity and higher levels of anxiety and reduced QOL among GERD patients ( 19, 20 ) . Yet, there is a paucity of work exploring ESOPHAGUS VOLUME 113 | JANUARY 2018
Yadlapati et al. MII-pH profi les: 11 off PPI therapy and 27 on PPI therapy. According to Rome IV, these groups represent functional (±GERD overlap) patients ( 21 ) . Th is is not only a prevalent group but also a mechanistically complex and therapeutically challengfactors associated with the patient's symptom experience within PPI non-responder phenotypes. More than one-third of all PPI non-responders in this study reported abnormal refl ux symptom burden despite normal ing population. Although psychological factors are commonly associated with functional heartburn, published studies supporting this notion are scarce ( 21 ). In our study, patients with negative pH results perceived symptoms in association with reduced QOL and greater psychosocial distress, rather than in association with objective fi ndings on MII-pH. Th ese results underscore the importance of reassurance, psychosocial support, and coping mechanisms for this particular population. Interestingly, abnormal symptom severity was also related to perceptions of dysphagia, as measured by the IDQ and BEDQ despite the majority demonstrating normal motility on manometry. Th ese results support the idea that functional heartburn and functional dysphagia exist on the same refl ux spectrum ( 21 ) . As such, use of nonpharmacological measures recommended for the management of functional dysphagia-such as eating upright, avoiding trigger items, careful chewing of food, and chasing food with liquidsmay be a reasonable treatment approach in functional heartburn patients who experience elevated levels of refl ux symptoms ( 21 ) . A demonstrable portion of PPI non-responders had abnormal acid exposure on PPI therapy, and met criteria for PPI refractory GERD ( 21 ) . Among patients with PPI refractory GERD, increased symptom perception was associated with higher SRA and a greater number of refl ux-associated symptoms on MII-pH monitoring. In fact, zero patients reporting normal symptom severity had a positive SRA, whereas 30% of patients reporting elevated symptom severity had a positive SRA. In addition, symptom severity among PPI refractory GERD patients was associated with lower esophageal contractility, suggesting a reduced clearance of refl uxate. Conversely, psychosocial factors were not related to symptom perception among patients with PPI refractory GERD. Th ese results suggest that actual refl ux events contribute to symptom perception, rather than psychosocial and environmental factors, in patients with PPI refractory GERD. Th us antirefl ux management strategies, such as increased acid suppression, refl ux inhibition, and restoration of the antirefl ux barrier, are appropriate treatment considerations for PPI refractory GERD patients experiencing troublesome symptoms.
Separate from functional heartburn, RHS requires a positive SRA on pH testing; however, current perspectives such as Rome IV posit that RHS is more akin to functional heartburn than GERD ( 21 ) . As expected, a small proportion of patients in this study with RHS reported normal symptom severity. As a result, the groups were underpowered to detect associations between symptom severity and physiological or psychosocial factors.
Strengths of this study include the prospective study design, classifi cation of patients based on objective and patient-reported outcome data, and sample size. As the group of patients with normal MII-pH results on PPI therapy represents a mix of pure functional and functional+PPI-controlled GERD overlap, we performed a post hoc analysis including patients with normal MII-pH results off PPI therapy in order to include a pure functional group. As certain questionnaires, such as the Brief Symptom Inventory, were introduced later in the study period, multivariable regression modeling to identify independent predictors of elevated symptom severity was not possible. Finally, this observational study is inherently unable to measure causality between factors and the outcome 
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Up to 50% of patients with refl ux symptoms do not respond adequately to proton pump inhibitor (PPI) therapy.
✓ Despite normal physiological profi les, PPI non-responders often perceive elevated levels of refl ux symptoms.
✓ Understanding drivers of symptom perception among PPI non-responder phenotypes is needed.
WHAT IS NEW HERE
✓ In PPI non-responders with normal physiology, symptom perception is associated with psychosocial distress and quality of life impairment.
✓ Alternatively, in PPI refractory gastroesophageal refl ux disease (GERD) symptom perception is associated with symptom-refl ux association.
of interest. Regardless of these limitations, our results support the interplay between psychosocial factors and symptom generation for PPI non-responders with normal physiology.
In conclusion, this prospective cohort analysis highlights variables associated with symptom perception according to PPI nonresponder phenotype. Increased symptom perception among PPI non-responders with normal MII-pH results was associated with perceptions of dysphagia, psychosocial distress, and reduced QOL. On the other hand, increased symptom perception in PPI refractory GERD was associated with objective SRA rather than psychosocial stressors and QOL impairment. Th ese results are important in understanding PPI non-responder phenotypes and formulating personalized management strategies.
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-AET/-SRA +AET -AET/-SRA +AET Figure 2 . Physiological data by symptom severity according to proton pump inhibitor (PPI) non-responder profi le. Among PPI refractory gastroesophageal refl ux disease patients, symptom severity is associated with the number of refl ux-associated symptoms and a lower distal contractile integral. * P <0.05. AET, acid exposure time; SRA, symptom-refl ux association. 
